by Eric Christianson | Jun 7, 2023 | Clinical Pharmacy News and New Drug Updates
A new SGLT2i is now on the market, promoting a new option for diabetes management. Bexagliflozin (Brenzavvy) got FDA approval in January of this year adding it to the list of SGLT2 inhibitors. With a few already on the scene, it bears the question, is bexagliflozin...
by Eric Christianson | Jan 12, 2022 | Clinical Guideline Updates For Pharmacists
The American Diabetes Association released their 2022 Diabetes Guidelines update. While I wouldn’t call the changes earth-shattering, there are some items in relation to pharmacotherapy that I feel are really important to note. The patient population that I work...
by Eric Christianson | Mar 10, 2021 | Clinical Guideline Updates For Pharmacists
There are a few important heart failure guideline updates in the works to the American College of Cardiology’s Heart Failure Guidelines, last published in 2013. Prior to the full guideline release, the organization recently printed their updated Expert Consensus...
by Eric Christianson | Dec 16, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists, Polypharmacy Cases And The Prescribing Cascade
SGLT2s like empagliflozin, dapagliflozin, ertugliflozin, and canagliflozin are getting more use in diabetes care as time goes on. As a geriatric pharmacist, I certainly recognize that these agents have a lot of potential benefits, but they can also have adverse...
by Eric Christianson | Jul 12, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Sodium-glucose co-transporter 2 inhibitors (SGLT2s) are becoming popular treatments for type 2 diabetes mellitus. While typically classified as diabetes medications, there is more and more research coming out for their benefits in cardiovascular health and heart...
